Fol. Biol. 2010, 56, 158-164
https://doi.org/10.14712/fb2010056040158
Advanced Rai Stage in Patients with Chronic Lymphocytic Leukaemia Correlates with Simultaneous Hypermethylation of Plural Tumour Suppressor Genes
References
1. 2005) Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma. J. Clin. Oncol. 23, 3940-3947.
< , R., Setien, F., Espada, J., Artiga, M. J., Rodriguez, M., Perez-Rosado, A., Sanchez-Aguilera, A., Fraga, M. F., Piris, M. A., Esteller, M. (https://doi.org/10.1200/JCO.2005.11.650>
2. 2007) Presence of simian virus 40 DNA sequences in diffuse large B-cell lymphomas in Tunisia correlates with aberrant promoter hypermethylation of multiple tumor suppressor genes. Int. J. Cancer 121, 2693-2702.
< , K., Trimeche, M., Ziadi, S., Laatiri, A., Hachana, M., Sriha, B., Mokni, M., Korbi, S. (https://doi.org/10.1002/ijc.23038>
3. 2008) Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann. Oncol. 19, 1774-1786.
< , K., Trimeche, M., Ziadi, S., Laatiri, A., Hachana, M. Korbi, S. (https://doi.org/10.1093/annonc/mdn374>
4. 2000) DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16, 168-174.
< , S. B., Herman, J. G. (https://doi.org/10.1016/S0168-9525(99)01971-X>
5. 1981) A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48, 198-206.
< , J. L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Oberling, F., Thomas, M., Tchernia, G., Jacquillat, C., Boivin, P., Lesty, C., Duault, M. T., Monconduit, M., Belabbes, S., Gremy, F. (https://doi.org/10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V>
6. 1997) Aand B-type lamins are differentially expressed in normal human tissues. Histochem. Cell Biol. 107, 505-517.
< , J. L., Machiels, B. M., Kuijpers, H. J., Smedts, F., van den Kieboom, R., Raymond, Y., Ramaekers, F. C. (https://doi.org/10.1007/s004180050138>
7. 2004) Laminopathies. J. Pathol. 204, 478-488.
< , J. L., Hutchison, C. J., Ramaekers, F. C. (https://doi.org/10.1002/path.1655>
8. 1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet. 11, 210-212.
< , P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L., Bova, G. S., Issacs, W., Schwab, D., Sidransky, D. (https://doi.org/10.1038/ng1095-210>
9. 2004) MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. USA 101, 11755-11760.
< , G. A., Liu, C. G., Sevignani, C., Ferracin, M., Felli, N., Dumitru, C. D., Shimizu, M., Cimmino, A., Zupo, S., Dono, M., Dell’Aquila, M. L, Alder, H., Rassenti, L., Kipps, T. J., Bullrich, F., Negrini, M., Croce, C. M. (https://doi.org/10.1073/pnas.0404432101>
10. 2005) MicroRNAs as regulators of mammalian hematopoiesis. Semin. Immunol. 17, 155-165.
< , C. Z., Lodish, H. F. (https://doi.org/10.1016/j.smim.2005.01.001>
11. 1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87, 4990-4997.
< , B. D., Bennett, J. M., Grever, M., Kay, N., Keating, M. J., O’Brien, S., Rai, K. R. (https://doi.org/10.1182/blood.V87.12.4990.bloodjournal87124990>
12. 2002)Hypermethylation of gene promoters in hematological neoplasia. Hematol. Oncol. 20, 167-176.
< , C.S.,Liang,R.,Kwong,Y.L.(https://doi.org/10.1002/hon.694>
13. 2004) SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia 18, 356-358.
< , C. S., Wong, K. Y., Loong, F., Srivastava, G. (https://doi.org/10.1038/sj.leu.2403216>
14. 2006) Methylation of INK4 and CIP/KIP families of cyclin-dependent kinase inhibitor in chronic lymphocytic leukaemia in Chinese patients. J. Clin. Pathol. 59, 921-926.
< , C. S., Fung, T. K., Wong, K. F., Lau, J. S., Law, M., Liang, R. (https://doi.org/10.1136/jcp.2005.035089>
15. 2007) Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J. Clin. Pathol. 60, 104-106.
< , C. S., Liang, R., Leung, M. H., Kwong, Y. L. (https://doi.org/10.1136/jcp.2006.036715>
16. 2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N. Engl. J. Med. 348, 1764-1775.
< , M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D., Rozman, M., Marcé, S., López-Guillermo, A., Campo, E., Montserrat, E. (https://doi.org/10.1056/NEJMoa023143>
17. 1995) Protein tyrosine phosphatase 1C negatively regulates antigen receptor signaling in B lymphocytes and determines thresholds for negative selection. Immunity 2, 13-24.
< , J. G., Goodnow, C. C. (https://doi.org/10.1016/1074-7613(95)90075-6>
18. 1999) IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840-1847.
< , R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S. L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S. M., Schulman, P., Vinciguerra, V. P., Rai, K. R., Ferrarinni, M., Chiorazzi, N. (https://doi.org/10.1182/blood.V94.6.1840>
19. 1997) 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood, 89, 2516-2522.
< , H., Stilgenbauer, S., James, M. R., Benner, A., Weilguni, T., Bentz, M. Fischer, K., Hunstein, W., Lichter, P. (https://doi.org/10.1182/blood.V89.7.2516>
20. 2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1910-1916.
< , H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Döhner, K., Bentz, M., Lichter, P. (https://doi.org/10.1056/NEJM200012283432602>
21. 1998) Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol. Cell. Biol. 18, 1793-1801.
< , S. A., Wong, D. J., Barrett, M. T., Galloway, D. A. (https://doi.org/10.1128/MCB.18.4.1793>
22. 2006) Aberrant methylation and deacetylation of deleted in liver cancer-1 gene in prostate cancer: potential clinical applications. Clin. Cancer Res. 12, 1412-1419.
< , M., Zhou, X., Soulitzis, N., Spandidos, D. A., Popescu, N. C. (https://doi.org/10.1158/1078-0432.CCR-05-1906>
23. 2003) Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood 102, 1035-1041.
< , A., Gaidano, G., Mauro, F. R., Capello, D., Mancini, F., De Propris, M. S., Mancini, M., Orsini, E., Gentile, M., Breccia, M., Cuneo, A., Castoldi, G., Foa, R.. (https://doi.org/10.1182/blood-2002-12-3639>
24. 1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848-1854.
< , T. J., Davis, Z., Gardiner, A., Oscier, D. G., Stevenson, F. K. (https://doi.org/10.1182/blood.V94.6.1848>
25. 2002) CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99, 1023-1029.
< , T. J., Orchard, J. A., Ibbotson, R. E., Davis, Z., Thomas, P. W., Stevenson, F. K., Oscier, D. G. (https://doi.org/10.1182/blood.V99.3.1023>
26. 1995) Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55, 4525-4530.
, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., Baylin, S. B. (
27. 1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821-9826.
< , J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., Baylin, S. B. (https://doi.org/10.1073/pnas.93.18.9821>
28. 1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 57, 837-841.
, J. G., Civin, C. I., Issa, J. P., Collector, M. I., Sharkis, S. J., Baylin, S. B. (
29. 2003) Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349, 2042-2054.
< , J. G., Baylin, S. B. (https://doi.org/10.1056/NEJMra023075>
30. 1995) Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 86, 841-854.
< , T., Koeffler, H. P. (https://doi.org/10.1182/blood.V86.3.841.841>
31. 2004) A-type lamins: guardians of the soma? Nat. Cell Biol. 6, 1062-1067.
< , C. J., Worman, H. J. (https://doi.org/10.1038/ncb1104-1062>
32. 1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436-440.
< , A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S. 3rd, Johnson, B. E., Skolnick, M. H. (https://doi.org/10.1126/science.8153634>
33. 2003) Transcriptional silencing of the DLC1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene 22, 3943-3951.
< , T. Y., Jong, H. S., Song, S. H., Dimtchev, A., Jeong, S. J., Lee, J. W., Kim, T. Y., Kim, N. K., Jung, M., Bang, Y. J. (https://doi.org/10.1038/sj.onc.1206573>
34. 2007) DLC1, a GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and migration in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 355, 72-77.
< , T. Y., Lee, J. W., Kim, H. P., Jong, H. S., Kim, T. Y., Jung, M., Bang, Y. J. (https://doi.org/10.1016/j.bbrc.2007.01.121>
35. 1995) Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature 375, 506-510.
< , J., Enders, G. H., Dynlacht, B. D. and Harlow, E. (https://doi.org/10.1038/375506a0>
36. 2003) Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab. Invest. 83, 1849-1858.
< , M., Oka, T., Ouchida, M., Nakatani, Y., Nishiuchi, R., Yoshino, T., Hayashi, K., Akagi, T., Seino, Y. (https://doi.org/10.1097/01.LAB.0000106503.65258.2B>
37. 2002) V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100, 1410-1416.
< , A., Seiler, T., Benner, A., Bullinger, L., Bruckle, E., Lichter, P., Döhner, H., Stilgenbauer, S. (https://doi.org/10.1182/blood.V100.4.1410.h81602001410_1410_1416>
38. 1997) Expression of nuclear lamins in human tissues and cancer cell lines and transcription from the promoters of the lamin A/C and B1 genes. Exp. Cell Res. 236, 378-384.
< , F., Worman, H. J. (https://doi.org/10.1006/excr.1997.3735>
39. 1997) De novo methylation of tumour suppressor genes CDKN2A and CDKN2B is a rare finding in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 99, 320-324.
< , V., Guerci, A., Humbert, J. C., Gregoire, M. J., Chery, M., Lederlin, P., Jonveaux, P. (https://doi.org/10.1046/j.1365-2141.1997.3953209.x>
40. 1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215.
< , S. A., Dykes, D. D., Polesky, H. F. (https://doi.org/10.1093/nar/16.3.1215>
41. 2000) DLC1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC1. Cancer Res. 60, 6581-6584.
, I. O., Liang, Z. D., Cao, L., Lee, T. K. (
42. 1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753-756.
< , T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., Carson, D. A. (https://doi.org/10.1038/368753a0>
43. 2002) Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 62, 6390-6394.
, T., Ouchida, M., Koyama, M., Ogama, Y., Takada, S., Nakatani, Y., Tanaka, T., Yoshino, T., Hayashi, K., Ohara, N., Kondo, E., Takahashi, K., Tsuchiyama, J., Tanimoto, M., Shimizu, K., Akagi, T. (
44. 2002) Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100, 1177-1184.
< , D. G., Gardiner, A. C., Mould, S. J., Glide, S., Davis, Z. A., Ibbotson, R. E., Corcoran, M. M., Chapman, R. M., Thomas, P., Copplestone, J. A., Orchard, J. A., Hamblin, T. J.H., (https://doi.org/10.1182/blood.V100.4.1177.h81602001177_1177_1184>
45. 1995) Identification of the tyrosine phosphatase PTP1C as a B cell antigen receptor-associated protein involved in the regulation of B cell signaling. J. Exp. Med. 181, 2077-2084.
< , G., Kozlowski, M., Cambier, J. C., Mills, G. B., Siminovitch, K. A. (https://doi.org/10.1084/jem.181.6.2077>
46. 2007) Hypermethylation of the p15INK4B gene promoter in Bchronic lymphocytic leukemia. Am. J. Hematol. 82, 824-825.
< , S. G., Lambropoulos, S., Pappa, V., Economopoulou, C., Kontsioti, F., Papageorgiou, E., Tsirigotis P, Dervenoulas, J., Economopoulos, T. (https://doi.org/10.1002/ajh.20914>
47. 2008) DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia 22, 1035-1043.
< , B. L., Greiner, T. C., Wang, X., Weisenburger, D. D., Hsu, Y. H., Renaud, G., Wolfsberg, T. G., Kim, M., Weisenberger, D. J., Siegmund, K. D., Ye, W., Groshen, S., Mehrian-Shai, R., Delabie, J., Chan, W. C., Laird, P. W., Hacia, J. G. (https://doi.org/10.1038/leu.2008.18>
48. 2003) Analysis of DLC1 expression in human breast cancer. J. Cancer Res. Clin. Oncol. 129, 349-354.
< , M., Seitz, S., Frege, R., Estevez-Schwarz, L., Scherneck, S. (https://doi.org/10.1007/s00432-003-0440-z>
49. 1975) Clinical staging of chronic lymphocytic leukemia. Blood 46, 219-234.
< , K. R., Sawitsky, A., Cronkite, E. P., Chanana, A. D., Levy, R. N., Pasternack, B. S. (https://doi.org/10.1182/blood.V46.2.219.219>
50. 2004) ZAP-70 compared with immunoglobulin heavychain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N. Engl. J. Med. 351, 893-901.
< , L. Z., Huynh, L., Toy, T. L., Chen, L., Keating, M. J., Gribben, J. G., Neuberg, D. S., Flinn, I. W., Rai, K. R., Byrd, J. C., Kay, N. E., Greaves, A., Weiss, A., Kipps, T. J. (https://doi.org/10.1056/NEJMoa040857>
51. 2005) Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 24, 732-736.
< , J., Shivapurkar, N., Takahashi, T., Parikh, G., Stastny, V., Echebiri, C., Crumrine, K., Zöchbauer-Müller, S., Drach, J., Zheng, Y., Feng, Z., Kroft, S. H., McKenna, R. W., Gazdar, A. F. (https://doi.org/10.1038/sj.onc.1208032>
52. 1989) Differential timing of nuclear lamin A/C expression in the various organs of the mouse embryo and the young animal: a developmental study. Development 105, 365-378.
< , R. A., Weber, K., Osborn, M. (https://doi.org/10.1242/dev.105.2.365>
53. 2000) DNA methylation in health and disease. Nat. Rev. Genet. 1, 11-19.
< , K. D., Wolffe, A. P. (https://doi.org/10.1038/35049533>
54. 2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J. Exp. Med. 194, 1639-1647.
< , A., Alizadeh, A. A., Widhopf, G., Simon, R., Davis, R. E., Yu, X., Yang, L., Pickeral, O. K., Rassenti, L. Z., Powell, J., Botstein, D., Byrd, J. C., Grever, M. R., Cheson, B. D., Chiorazzi, N., Wilson, W. H., Kipps, T. J., Brown, P. O., Staudt, L. M. (https://doi.org/10.1084/jem.194.11.1639>
55. 2004) Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res. 64, 2424-2433.
< , L. J., Raval, A., Funchain, P., Johnson, A. J., Smith, L., Lucas, D. M., Bembea, M., Liu, T. H., Heerema, N. A., Rassenti, L., Liyanarachchi, S., Davuluri, R., Byrd, J. C., Plass, C. (https://doi.org/10.1158/0008-5472.CAN-03-2870>
56. 2009) CpG island methylation patterns in chronic lymphocytic leukemia. Leuk. Lymphoma 50, 419-426.
< , B., Wilop, S., Osieka, R., Galm, O., Jost, E. (https://doi.org/10.1080/10428190902756594>
57. 2007) The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene 26, 934-944.
< , T. J., Low, J. S., Li, H., Cui, Y., Goh, H. K., Wong, M. L., Srivastava, G., Sidransky, D., Califano, J., Steenbergen, R. D., Rha, S. Y., Tan, J., Hsieh, W. S., Ambinder, R. F., Lin, X., Chan, A. T., Tao, Q. (https://doi.org/10.1038/sj.onc.1209839>
58. 2007) Discovery of novel epigenetic markers in non-Hodgkin’s lymphoma. Carcinogenesis 28, 60-70.
< , H., Guo, J., Duff, D. J., Rahmatpanah, F., ChitimaMatsiga, R., Al-Kuhlani, M., Taylor, K. H., Sjahputera, O., Andreski, M., Wooldridge, J. E., Caldwell, C. W. (https://doi.org/10.1093/carcin/bgl092>
59. 1999) DNA methylation. Blood 93, 4059-4070.
< , R., Ginder, G. D. (https://doi.org/10.1182/blood.V93.12.4059>
60. 2006) High-frequency promoter hypermethylation of the deleted in liver cancer-1 gene in multiple myeloma. J. Clin. Pathol. 59, 947-951.
< , Y. F., Xu, R., Zhang, X. H., Chen, B. B., Chen, Q., Chen, Y. M., Xie, Y. (https://doi.org/10.1136/jcp.2005.031377>
61. 1990) Repression of nuclear lamin A and C gene expression in human acute lymphoblastic leukemia and non-Hodgkin’s lymphoma cells. Leuk. Res. 14, 815-821.
< , B., Khandjian, E., Hirt, A., Luthy, A., Weil, R., Wagner, H. P. (https://doi.org/10.1016/0145-2126(90)90076-L>
62. 2002) Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 16, 993-1007.
< , S., Bullinger, L., Lichter, P., Dohner, H. (https://doi.org/10.1038/sj.leu.2402537>
63. 2001) CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. Blood 97, 1892-1894.
< , U., Johnson, A., Roos, G., Thorn, I., Tobin, G., Sallstrom, J., Sundström, C., Rosenquist, R. (https://doi.org/10.1182/blood.V97.6.1892>
64. 2006) Mutational and methylation analysis of the cyclin-dependent kinase 4 inhibitor (p16INK4A) gene in chronic lymphocytic leukemia. Eur. J. Haematol. 76, 230-236.
< , P., Pappa, V., Labropoulos, S., Papageorgiou, S., Kontsioti, F., Dervenoulas, J., Papageorgiou, E., Panani, A., Mantzios, G., Economopoulos, T., Raptis, S. (https://doi.org/10.1111/j.1600-0609.2005.00604.x>
65. 2006) Expression profile of the tumor suppressor genes DLC1 and DLC-2 in solid tumors. Int. J. Oncol. 29, 1127-1132.
, V., Popescu, N. C. (
66. 2003) Binet’s staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J. Clin. Oncol. 21, 3928-3932.
< , Y., Davi, F., Levy, V., Oppezzo, P., Magnac, C., Michel, A., Yamamoto, M,, Pritsch, O., Merle-Béral, H., Maloum, K., Ajchenbaum-Cymbalista, F., Dighiero, G. (https://doi.org/10.1200/JCO.2003.02.134>
67. 2003) Genetic and epigenetic alterations of DLC1 gene in hepatocellular carcinoma. Cancer Res. 63, 7646-7651.
, C. M., Lee, J. M., Ching, Y. P., Jin, D. Y., Ng, I. O. (
68. 2007) Tumor-specific methylation of the 8p22 tumor suppressor gene DLC1 is an epigenetic biomarker for Hodgkin, nasal NK/T-cell and other types of lymphomas. Epigenetics 2, 15-21.
< , J., Li, H., Murray, P., Gao, Z., Chen, Y. W., Wang, Y., Lee, K. Y., Chan, A. T., Ambinder, R. F., Srivastava, G., Tao, Q. (https://doi.org/10.4161/epi.2.1.3883>
69. 1998) Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC1) homologous to rat RhoGAP. Cancer Res. 58, 2196-2199.
, B. Z., Miller, M. J., Keck, C. L., Zimonjic, D. B., Thorgeirsson, S. S., Popescu, N. C. (
70. 2003) Promoter hypermethylation of DLC1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet. Cytogenet. 140, 113-117.
< , B. Z., Durkin, M. E., Popescu, N. C. (https://doi.org/10.1016/S0165-4608(02)00674-X>
71. 2004) DLC1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 23, 1405-1411.
< , B. Z., Jefferson, A. M., Baldwin, K. T., Thorgeirsson, S. S., Popescu, N. C., Reynolds, S. H. (https://doi.org/10.1038/sj.onc.1207291>
72. 2000) Lack of phosphotyrosine phosphatase SHP1 expression in malignant T-cell lymphoma cells results from methylation of the SHP1 promoter. Am. J. Pathol. 157, 1137-1146.
< , Q., Raghunath, P. N., Vonderheid, E., Odum, N., Wasik, M. A. (https://doi.org/10.1016/S0002-9440(10)64629-9>